July 17, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Pegcetacoplan slows photoreceptor and retinal pigment epithelium loss in patients with geographic atrophy only as well as patients with GA and concurrent wet age-related macular degeneration, according to a speaker.At the American Society of Retina Specialists annual meeting. Hasenin Al-khersan, MD, presented findings from a retrospective study of 240 eyes of 199 patients using data from the
July 17, 2026
3 min watch
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Vision Benefits in GA With Complement Inhibitor, Regardless of AMD, Anti-VEGF

Stem Cell Therapy for GA Shows Early Evidence of Vision Gains, Retina Preservation

Inflammasome Therapeutics Reports Positive Six-Month Phase 2 Results for K8 in Geographic Atrophy

Anti-VEGF Continuous Delivery Device Preserves Vision, Retinal Anatomy in DME

Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration

Largest effects seen in eyes with GA and AMD, dual treatment with pegcetacoplan, VEGF inhibitor

DENVER — In a phase 1b trial, subretinal delivery of a human stem cell-derived retinal pigment epithelium yielded visual…

LAS VEGAS — Customized microperimetry helped researchers track geographic atrophy in patients undergoing CTx001 gene therapy,…

DENVER — A real-world analysis showed increased rates of undertreatment and attrition with anti-VEGF injections in patients with…

LONG BEACH, Calif. — Patients treated with Encelto who had smaller baseline ellipsoid zone area loss had better treatment…

ASP7317 may offer potential to improve vision and repair retina, not just slow down atrophy